Physician profile
Taylor Parrish
NPI 1962009050
$9,351.24
in general payments reported to CMS, 2019-2025
36 companies · $2,092 in 2025
The $2,092 reported for 2025 was more than what 93% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $3,583 · 2023: $2,237 · 2024: $1,440 · 2025: $2,092.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,745 · Education: $15.10 · Travel and Lodging: $8.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,745.27 |
| Education | $15.10 |
| Travel and Lodging | $8.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $2,091.66 | 2022-2023 | Minimed 780g |
| Lilly USA, LLC | $1,534.85 | 2022-2025 | Mounjaro, Jardiance, Zepbound |
| Novo Nordisk INC | $806.80 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $765.72 | 2022-2025 | Evenity, Prolia, Tepezza |
| Abbott Laboratories | $729.32 | 2022-2025 | Freestyle Libre 3 |
| Sanofi-Aventis U.S. LLC | $420.14 | 2022-2025 | |
| Radius Health, INC. | $351.68 | 2023-2025 | Tymlos |
| Dexcom, INC. | $350.30 | 2022-2025 | Dexcom G6 Transmitter |
| Bayer Healthcare Pharmaceuticals INC. | $329.08 | 2022-2025 | |
| Mannkind Corporation | $308.95 | 2022-2025 | Afrezza |
| Insulet Corporation | $289.32 | 2022-2025 | Omnipod |
| Astrazeneca Pharmaceuticals LP | $263.43 | 2022-2025 | Farxiga, Lokelma |
| Ascendis Pharma Endocrinology INC | $161.68 | 2024-2025 | Yorvipath |
| Corcept Therapeutics | $125.88 | 2022-2025 | Korlym |
| Boehringer Ingelheim Pharmaceuticals, INC. | $96.58 | 2022-2024 | Jardiance |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $89.51 | 2022-2025 | |
| Tolmar, INC. | $78.50 | 2023-2025 | Jatenzo |
| Alexion Pharmaceuticals, INC. | $77.25 | 2022-2024 | Strensiq |
| Recordati_rare_diseases_inc. | $60.78 | 2022-2025 | Isturisa, Signifor Lar |
| Merck Sharp & Dohme LLC | $57.26 | 2022-2023 | Steglatro, Steglujan |
| Tandem Diabetes Care, INC. | $42.58 | 2024 | T:Slim X2 Insulin Pump With Control-Iq |
| Madrigal Pharmaceuticals | $34.82 | 2025 | Rezdiffra |
| Averitas Pharma INC. | $32.97 | 2024-2025 | Qutenza |
| Chiesi USA, INC. | $29.41 | 2024-2025 | Mycapssa |
| Novartis Pharmaceuticals Corporation | $23.32 | 2024 | |
| Amryt Pharma Holdings LTD | $22.26 | 2023 | Mycapssa |
| Xeris Pharmaceuticals, INC. | $21.22 | 2022 | |
| Rgh Enterprises LLC | $19.34 | 2024 | |
| Ibsa Pharma INC. | $19.26 | 2024 | Tirosint, Licart |
| Bigfoot Biomedical INC | $18.71 | 2022 | |
| Amneal Pharmaceuticals LLC | $18.59 | 2023 | Unithroid |
| Beta Bionics, INC. | $18.28 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Rhythm Pharmaceuticals, INC. | $17.82 | 2025 | Imcivree |
| Becton, Dickinson and Company | $15.37 | 2022 | |
| Opko Pharmaceuticals, LLC | $15.10 | 2023 | Rayaldee |
| Eusa Pharma (US) LLC | $13.50 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Taylor Parrish listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.